UPRCCC/MDACC: Partnership for Excellence in Cancer Research (1 of 2)

UPRCCC/MDACC：癌症研究卓越合作伙伴关系（2 中的 1）

• 批准号: 8609637
• 负责人: Michelle Ann Barton
• 金额: $ 107.78万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-16 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8609637
• 关键词: Address; Affect; African; Award; Body mass index; Cancer Burden; Cancer Center; Clinic; Collaborations; Colorectal Cancer; Comprehensive Cancer Center; Data; Development; Diagnosis; Early Diagnosis; Education and Outreach; Educational Curriculum; Faculty; Fostering; Funding; Genetic Markers; Goals; Grant; Hispanics; Hospitals; Hyperthermia; Incidence; Institution; Interdisciplinary Study; Magnetism; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Medicine; National Cancer Program; Outreach Research; Physicians; Pilot Projects; Positioning Attribute; Prevalence; Prevention; Puerto Rican; Puerto Rico; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Training; Role; Scientist; Services; Smoking Cessation Intervention; Socioeconomic Status; Staging; Structure; Training; Training and Education; Translational Research; Universities; University of Texas M D Anderson Cancer Center; Work; anticancer research; base; cancer education; cancer health disparity; cancer risk; career development; design; health disparity; interest; mortality; nanoparticle; oncology; outreach program; success; survivorship; tumor

DESCRIPTION (provided by applicant): This is a renewal application for the Partnership for Excellence in Cancer Research between The University of Puerto Rico (UPR) and The University of Texas MD Anderson Cancer Center (MDACC). The Partnership proposes structured initiatives to further enhance the research infrastructure within these two institutions to reduce the burden of cancer health disparities. Funds granted in this award will be used to support two full and one pilot research projects. The first full project examines the role of West African ancestry in prostate cancer risk and aggressiveness. Pilot data show an association of several ancestral genetic markers, body mass index, and socioeconomic status with higher-grade prostate cancer. The second full project focuses on magnetic nanoparticle based hyperthermia for ovarian cancer. Pilot project data show a marked decrease in the associated tumor size when treated with nanoparticles. The pilot study is a smoking cessation intervention in oncology clinics. Together, these projects comprise a multidisciplinary research portfolio representing the T l to T3 stages of the translational research continuum. Partnership funds will also be used to: 1) enhance existing collaborations and establish new collaborations; 2) restructure the training pipeline to include customized career development tracks for physicians, scientists and physician scientists interested in cancer medicine to accelerate the development of a critical mass of faculty for the UPR Comprehensive Cancer Center (UPRCCC); 3) implement a cancer education curriculum; and 4) maintain and expand the Outreach Program, including core services and an outreach research project designed to reduce the burden of colorectal cancer among Puerto Ricans. Thus far, the Partnership has established a dynamic collaborative team that is working towards fortifying and stabilizing the developing infrastructure at the UPRCCC as evidenced by a newly constructed UPRCCC Research Center (opened 6/2009); the UPRCCC hospital will be completed in 2016. Funding for a second renewal is critical to cement and build on the substantial momentum and success achieved by the Partnership over the last ten years. The Partnership is poised to fulfill its long-term goal of positioning the UPRCCC to become a frontrunner in addressing health disparities that affect Hispanic populations across the cancer continuum (prevention, early detection, diagnosis, treatment and survivorship). RELEVANCE: This renewal seeks to foster and support an existing collaboration between the UPR and MDACC. By addressing differences in incidence, prevalence, mortality, and burden of cancer that exist among Hispanic populations in the US, the Partnership strives to reduce these disparities through efforts in Cancer Research, Training, Education and Outreach. Partnership contributions will also aid in building a stronger national cancer program through the development of a pipeline of well-trained, Hispanic cancer researchers.

描述（由申请人提供）：这是波多黎各大学（UPR）和德克萨斯大学医学博士Anderson癌症中心（MDACC）之间癌症研究卓越合作伙伴关系的续签申请。伙伴关系提出了结构化计划，以进一步增强这两个机构中的研究基础设施 减轻癌症健康差异的负担。该奖项授予的资金将用于支持两个完整的和一个试点研究项目。第一个完整的项目研究了西非血统在前列腺癌风险和侵略性中的作用。试验数据显示，几种祖先遗传标记，体重指数和社会经济状况与高级前列腺癌的关联。第二个完整的项目着重于基于磁性纳米颗粒的卵巢癌的高温。试点项目数据显示，用纳米颗粒处理相关的肿瘤大小显着减少。试点研究是对肿瘤学诊所的戒烟干预。这些项目共同组成了一个多学科研究组合，代表转化研究连续体的T3阶段。合伙基金还将用于：1）增强现有合作并建立新的合作； 2）重组培训管道，包括针对对癌症医学感兴趣的医师，科学家和医师科学家的定制职业发展轨道，以加快为UPR综合癌症中心（UPRCCC）的批判性教师的发展； 3）实施癌症教育课程； 4）维护和扩大外展计划，包括核心服务和旨在减轻波多黎各人大肠癌负担的外展研究项目。到目前为止，该合作伙伴关系已经建立了一个动态的合作团队，该团队正在努力加强和稳定发展的基础设施 在UPRCCC上，新建的UPRCCC研究中心（开放6/2009）证明了这一点； UPRCCC医院将于2016年完成。第二次续约的资金对于巩固和建立在过去十年中伙伴关系取得的巨大动力和成功基础上至关重要。该合作伙伴关系有望实现其将UPRCCC定位为解决癌症连续性西班牙裔人群的健康差异（预防，早期发现，诊断，治疗，治疗和生存）的长期目标。 相关性：这种更新旨在促进和支持UPR与MDACC之间的现有合作。通过解决美国西班牙裔人群中存在的癌症的发病率，患病率，死亡率和负担的差异，伙伴关系致力于通过在癌症研究，培训，教育和外展方面的努力来减少这些差异。伙伴关系贡献还将通过开发训练有素的西班牙裔癌症研究人员的渠道来帮助建立更强大的国家癌症计划。